ĐÁNH GIÁ HIỆU QUẢ ĐIỀU TRỊ CỦA PHÁC ĐỒ ARV TDF+3TC+DTG TRÊN BỆNH NHÂN HIV/AIDS TẠI BỆNH VIỆN ĐA KHOA ĐỐNG ĐA 2020-2021

Abstract

HIV/AIDs infection is a burden of disease for patients and their families and society as a whole. Anti-retroviral drugs(ARV) are the optimal treatment forhiv/AIDS patients. 

Objective: 1. Assess the therapeutic effectiveness of TDF + 3TC + DTG regimen in HIV/AIDS patients at Dong Da General Hospital. Comment on the undesirable effects and a number of factors that affect the therapeutic effect of this regimen. 

Subjects and methods: The study involved 61 patients diagnosed with HIV/AIDS and treated with the TDF+3TC+DTG regimen followed for a full 24 weeks, between February 202 and June 2021. Retrospective cross-description study. 

Results: Weight, BMI and CD4 count increases statistically (p<0.05) at the time after 24 weeks of treatment. 45/61 (73.8%) of patients reached the maximum level of the virus (below the detection threshold). Adherence to treatment is associated with post-treatment viral load (OR=2.32 CI 95% 0.21-8.643, p<0.05). 

Conclusions: The TDF+3TC+DTG ARV drug regimen has a good treatment effect in patients with HIV/AIDS (weight, CD4 increases after 24 weeks of treatment and the virus is inhibited at a high rate). The group of patients who adhered to good treatment had a maximum of 2.32 times the ability to suppress the virus with a group that adhered to bad treatment.